Atlas Trials

Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma

Clinical trial NCT06827782 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT06827782
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
ENROLLING_BY_INVITATION
Phase
Phase 1
Study type
INTERVENTIONAL
Refractory/Recurrent Central Nervous System Lymphoma
Start date
2025-03-01
Primary completion
2026-12-31
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.